Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2002

View Archived Issues

Memantine induces neuroprotection in rats and is effective for treating dementia in humans

Synthesis and efficacy of two novel orally active antimalarial synthetic 3-carboxyphenyltrioxanes

Periostat enters phase III trial for the treatment of rosacea

CAT and Xerion enter allergy target research collaboration

VitrenASE enters phase II trial in proliferative vitreoretinopathy

Pivotal Alprox-TD studies complete enrollment

Growth hormone reverses thymic atrophy in HIV-infected men

Antithrombotic efficacy of MAb-LE2E9 shown in a murine model of venous thrombosis

Skin permeation of miconazole is enhanced by hydrogenated soybean lecithin and DDAIP formulations

New hypolipidemic agents emerging from Aventis R&D

New erythromycin A derivatives in early development at GSK

Lilly claims sPLA2 inhibitors with potential in sepsis and other inflammatory disorders

Selective procollagen C-proteinase inhibitors presented by Pfizer

Antioxidant epicatechin derivatives for use in cancer, cardiovascular disorders, etc.

Elidel receives positive health authority decision in 13 European countries

OSI and Genentech update progress of Tarceva development program

Results on FTase inhibitor SCH-400 presented at ACS

Merck reports novel KDR inhibitors at ACS meeting

In vitro and in vivo characterization of new KDR inhibitors disclosed by Merck

Wyeth scientists identify novel inhibitors of B7.1-CD28 interaction

New cathepsin S inhibitors designed by Boehringer Ingelheim researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...